Quoin Pharmaceuticals Ltd.
13F holders, Q1 2025 (March 31)9holders −5
4new positions
9sold out
$0.22avg. 13F price*
At the end of Q1 2025, 9 institutions reported holding Quoin Pharmaceuticals Ltd. in their 13F filings, down 5 from Q4 2024. 4 opened new positions and 9 sold out. The largest holders were UBS Group AG ($49K), Apollon Wealth Management, LLC ($18K) and Rhumbline Advisers ($10K).
- Company
- Quoin Pharmaceuticals Ltd.
- CUSIP
- 74907L300
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $8K |
| Exits | 9 | $919K |
All 13F filers, Q4 2024 → Q1 2025: 267,462 shares bought and 1,412,394 shares sold, net −1,144,932 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| UBS Group AG | 0.00% | Add +4494.5% | 219,295 | $49K |
| Apollon Wealth Management, LLC | 0.00% | No change | 80,025 | $18K |
| Rhumbline Advisers | 0.00% | Add +73.0% | 41,741 | $10K |
| Raymond James Financial Inc. | 0.00% | No change | 25,119 | $6K |
| Lido Advisors, LLC | 0.00% | New | 23,515 | $5K |
| Susquehanna International Group, LLP | 0.00% | New | 11,210 | $3K |
| Morgan Stanley | 0.00% | New | 456 | $102 |
| JPMorgan Chase & Co. | 0.00% | New | 144 | $33 |
| Raiffeisen Bank International AG | 0.00% | No change | 17 | $4 |
"% of holder's portfolio" is QUOIN PHARMACEUTICALS LTD's weight in each manager's 13F, not the share of Quoin Pharmaceuticals Ltd. the manager owns.